A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Advanced Cancer
Interventions
DRUG

Sativex

Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.

Sponsors
All Listed Sponsors
lead

GW Pharmaceuticals Ltd

INDUSTRY

NCT02432612 - A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter